Systemic analgesia and co-analgesia

Area of Science:

• Anesthesiology
• Pharmacology
• Pain Management

Background:

• Opioids are effective analgesics but cause significant side effects.
• Co-analgesics are used to mitigate opioid-related adverse events and improve analgesia.
• Opioid-induced bowel dysfunction and postoperative ileus are common challenges.

Purpose of the Study:

• To review the literature on co-analgesics used with opioids.
• To evaluate the impact of co-analgesics on opioid side effects and consumption.
• To assess the efficacy of specific agents in managing opioid-induced adverse events.

Main Methods:

• Literature search of recent studies on co-analgesics and opioid therapy.
• Analysis of data regarding the effects of co-analgesics on opioid side effects (e.g., nausea, vomiting, bowel dysfunction).
• Evaluation of the impact on opioid consumption and analgesia quality.

Main Results:

• Peripheral opioid antagonists reduce opioid-induced bowel dysfunction without affecting analgesia.
• Dexmedetomidine, gabapentin, and ketamine reduce opioid consumption but not side effect incidence.
• Intravenous lidocaine and corticosteroids reduce opioid consumption and significantly decrease postoperative ileus, nausea, and vomiting.

Conclusions:

• Co-analgesics offer a strategy to manage opioid-related side effects and reduce opioid requirements.
• Peripheral opioid antagonists are effective for opioid-induced bowel dysfunction.
• Lidocaine and corticosteroids show promise in reducing postoperative ileus and nausea/vomiting, but their effect on chronic pain requires further investigation.